New combo trial hopes to tame advanced breast cancer
NCT ID NCT07427394
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 3 times
Summary
This study tests two experimental drugs, camizestrant and atirmociclib, in 24 people with a specific type of advanced breast cancer (ER-positive, HER2-negative) that has worsened after prior treatment. The main goal is to check safety and how the body processes the drugs, with early signs of tumor control also measured. This is not a cure; it aims to manage the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
RECRUITINGSt Louis, Missouri, 63108, United States
-
Research Site
NOT_YET_RECRUITINGEast Providence, Rhode Island, 02915, United States
-
Research Site
RECRUITINGNashville, Tennessee, 37203, United States
-
Research Site
RECRUITINGCambridge, CB2 0QQ, United Kingdom
-
Research Site
RECRUITINGLondon, EC1M6BQ, United Kingdom
-
Research Site
RECRUITINGManchester, M20 4GJ, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Step drug combo outsmart advanced HER2-Positive breast cancer?
- Can a pill combo outpace chemotherapy for aggressive breast cancer?
- Blood tests could reveal hidden resistance in breast cancer
- Triple threat: three new targeted drugs join forces with immunotherapy to attack Hard-to-Treat breast cancer
- New drug sequence aims to outsmart advanced breast cancer
- Could a pill replace an IV for advanced breast cancer treatment?